Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease

European Journal of Haematology

Volumn 98, Issue 6, 2017, Pages 608-614

  Badawy, Sherif M ^a,b   Thompson, Alexis A ^a   Penedo, Frank J ^a   Lai, Jin Shei ^a   Rychlik, Karen ^a   Liem, Robert I ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

adherence; adolescents and young adults; barriers; compliance; health related quality of life; hydroxyurea; patient reported outcomes; patient reported outcomes measurement information system; PROMIS ; sickle cell

Indexed keywords

HYDROXYUREA; ANTISICKLING AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DEPRESSION; FATIGUE; FEMALE; HUMAN; INFORMATION SYSTEM; MALE; MEAN CORPUSCULAR VOLUME; MEDICATION COMPLIANCE; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PAIN; PATIENT COMPLIANCE; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; QUALITY OF LIFE; SICKLE CELL ANEMIA; VISUAL ANALOG SCALE; YOUNG ADULT; CHILD; PAIN MEASUREMENT; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOLOGY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROXYUREA; MALE; MEDICATION ADHERENCE; PAIN MEASUREMENT; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85018577939     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12878     Document Type: Article

References (38)

1. Panepinto JA, Bonner M. Health-related quality of life in sickle cell disease: past, present, and future. Pediatr Blood Cancer. 2012;59:377-385.
2. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376:2018-2031.
3. Boulet SL, Yanni EA, Creary MS, et al. Health status and healthcare use in a national sample of children with sickle cell disease. Am J Prev Med. 2010;38(4 Suppl):S528-S535.
4. Candrilli SD, O'Brien SH, Ware RE, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol. 2011;86:273-277.
5. Thornburg CD, Calatroni A, Panepinto JA. Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. J Pediatr Hematol Oncol. 2011;33:251-254.
6. Wang WC, Oyeku SO, Luo Z, et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics. 2013;132:677-683.
7. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377:1663-1672.
8. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317-1322.
9. Loiselle K, Lee JL, Szulczewski L, et al. Systematic and meta-analytic review: medication adherence among pediatric patients with sickle cell disease. J Pediatr Psychol. 2016;41:406-418.
10. Thornburg CD, Calatroni A, Telen M, et al. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr. 2010;156:415-419.
11. Badawy SM, Thompson AA, Liem RI. Technology access and smartphone app preferences for medication adherence in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer. 2016;63:848-852.
12. Walsh KE, Cutrona SL, Kavanagh PL, et al. Medication adherence among pediatric patients with sickle cell disease: a systematic review. Pediatrics. 2014;134:1175-1183.
13. Badawy SM, Thompson AA, Lai JS, et al. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer. 2016; doi: 10.1002/pbc.26369.
14. Haywood C Jr, Beach MC, Bediako S, et al. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. Am J Hematol. 2011;86:85-87.
15. Brandow AM, Panepinto JA. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. Am J Hematol. 2011;86:804-806.
16. Staples B, Bravender T. Drug compliance in adolescents: assessing and managing modifiable risk factors. Paediatr Drugs. 2002;4:503-513.
17. Smith BA, Shuchman M. Problem of nonadherence in chronically ill adolescents: strategies for assessment and intervention. Curr Opin Pediatr. 2005;17:613-618.
18. KyngAs HA, Kroll T, Duffy ME. Compliance in adolescents with chronic diseases: a review. J Adolesc Health. 2000;26:379-388.
19. Svarstad BL, Chewning BA, Sleath BL, et al. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37:113-124.
20. Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10:348-354.
21. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS. 2002;16:269-277.
22. Varni JW, Magnus B, Stucky BD, et al. Psychometric properties of the PROMIS (R) pediatric scales: precision, stability, and comparison of different scoring and administration options. Qual Life Res. 2014;23:1233-1243.
23. DeWalt DA, Gross HE, Gipson DS, et al. PROMIS((R)) pediatric self-report scales distinguish subgroups of children within and across six common pediatric chronic health conditions. Qual Life Res. 2015;24:2195-2208.
24. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010;63:1179-1194.
25. Dampier C, Barry V, Gross HE, et al. Initial evaluation of the pediatric PROMIS(R) health domains in children and adolescents with sickle cell disease. Pediatr Blood Cancer. 2016;63:1031-1037.
26. Dampier C, Jaeger B, Gross HE, et al. Responsiveness of PROMIS pediatric measures to hospitalizations for sickle pain and subsequent recovery. Pediatr Blood Cancer. 2016;63:1038-1045.
27. Irwin DE, Stucky BD, Thissen D, et al. Sampling plan and patient characteristics of the PROMIS pediatrics large-scale survey. Qual Life Res. 2010;19:585-594.
28. Ballas SK, Barton FB, Waclawiw MA, et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes. 2006;4:59.
29. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
30. Sabate E. Adherence to Long-term Therapies: Evidence for Action. Geneva: World Health Organization; 2003. Available at: http://apps.who.int/iris/bitstream/10665/42682/1/9241545992.pdf (Accessed June 3, 2016).
31. Yost KJ, Eton DT, Garcia SF, et al. Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011;64:507-516.
32. Thissen D, Liu Y, Magnus B, et al. Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale-judgment method. Qual Life Res. 2016;25:13-23.
33. Hassell KL. Population estimates of sickle cell disease in the US. Am J Prev Med. 2010;38(4 Suppl.):S512-S521.
34. DeBaun MR, Telfair J. Transition and sickle cell disease. Pediatrics. 2012;130:926-935.
35. Creary S, Zickmund S, Ross D, et al. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision. BMC Res Notes. 2015;8:372.
36. Stirratt MJ, Dunbar-Jacob J, Crane HM, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015;5:470-482.
37. Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood. 2002;99:10-14.
38. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115:5300-5311.